Cardinal, Biosensors Ink Distribution Deal

Cardinal Health is diving into the drug-eluting stent market, inking a distribution agreement with Biosensors to sell Biosensors’ coronary stent portfolio.

Under the agreement, Cardinal’s interventional vascular arm — Cordis — will market the stents in Europe, the Middle East, Africa, Australia and New Zealand.

Biosensors’ coronary stent portfolio includes BioFreedom, the BioMatrix NeoFlex, BioMatrix Alpha and the Chroma. — Anisa Jibrell